Meeting News
Advertisement
The Clever-1 targeting antibody is currently under evaluation in clinical trials as part of a combination therapy.
Mitochondrial targeting strategies could be combined with chemotherapy as part of induction and consolidation for AML.
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
The estimated 24-month nonrelapse mortality was significantly lower in the CAR-T cohort than in the allogeneic HSCT cohort.
The research shows an emerging target for the development of novel CAR T-cell immunotherapies.
Advertisement
The researchers reported “high rates of durable responses” in most patients who were in high-risk disease subgroups.
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Michael Dickinson, MBBS, DMedSc, discusses updates on glofitamab that were presented during the 2022 ASH meeting.
Shambavi Richard, discusses a retrospective study on extramedullary disease and CAR-T in multiple myeloma.
Simona Soverini, PhD, discusses new molecular data on CML, remaining challenges, and potentially practice-changing data.
Ajai Chari, MD, of Mount Sinai School of Medicine, discusses results from the MonumenTAL-1 phase I/II study of talquetamab.
Patients with multiple myeloma receiving BCMA-targeted therapies are at high risk of infectious complications.
Sarah Tasian, MD, of the Children's Hospital of Philadelphia, talks with The HemOnc Pulse about pediatric oncology.
A simulation approach identified odronextamab dosing regimens that could be used in children with aggressive NHL.
Race/ethnicity, income, and access to chemotherapy and radiation therapy improved outcomes in patients with Burkitt lymphoma.
The cell of origin in patients with diffuse large B-cell lymphoma may impact their response to CAR-T therapy and survival.
Patients with ALL who underwent allogeneic HSCT in their first complete remission had a two-year OS rate of 73.9%.
Cachexia could be used as a prognostic marker for survival after CAR-T therapy in patients with aggressive B-cell lymphoma.
In follow-up data from the phase II CAPTIVATE study, ibrutinib plus venetoclax demonstrated a favorable benefit-risk profile.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726